Rep. Gilbert Ray Cisneros, Jr. Acquires Biogen Inc. (NASDAQ:BIIB) Shares

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Biogen Inc. (NASDAQ:BIIB). In a filing disclosed on July 02nd, the Representative disclosed that they had bought between $1,001 and $15,000 in Biogen stock on June 5th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of The Descartes Systems Group (NASDAQ:DSGX) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of Texas Roadhouse (NASDAQ:TXRH) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of Texas Capital Bancshares (NASDAQ:TCBI) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of Microchip Technology (NASDAQ:MCHP) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 6/30/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 6/30/2026.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 6/30/2026.

Biogen Stock Performance

NASDAQ BIIB remained flat at $216.12 during midday trading on Friday. The company’s stock had a trading volume of 1,154,423 shares, compared to its average volume of 1,149,002. The business has a fifty day moving average of $196.61 and a 200-day moving average of $187.03. The stock has a market cap of $31.91 billion, a P/E ratio of 23.19 and a beta of 0.16. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. Biogen Inc. has a 52-week low of $121.05 and a 52-week high of $219.72.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period in the prior year, the firm posted $3.02 EPS. Biogen’s quarterly revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, equities analysts anticipate that Biogen Inc. will post 13.95 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Wedbush boosted their target price on shares of Biogen from $191.00 to $196.00 and gave the company a “neutral” rating in a research report on Thursday, April 30th. Royal Bank Of Canada lifted their price objective on shares of Biogen from $222.00 to $227.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. Freedom Capital upgraded shares of Biogen from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. HC Wainwright restated a “buy” rating on shares of Biogen in a research note on Thursday, May 14th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $225.00 target price (up from $214.00) on shares of Biogen in a report on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $217.41.

Institutional Trading of Biogen

A number of hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC boosted its position in Biogen by 1,793.8% during the 4th quarter. SG Americas Securities LLC now owns 183,829 shares of the biotechnology company’s stock worth $32,352,000 after buying an additional 174,122 shares during the period. Farmers Trust Co. increased its position in Biogen by 27.8% in the 4th quarter. Farmers Trust Co. now owns 33,185 shares of the biotechnology company’s stock valued at $5,840,000 after acquiring an additional 7,214 shares during the period. LSV Asset Management raised its stake in shares of Biogen by 3.3% during the fourth quarter. LSV Asset Management now owns 316,815 shares of the biotechnology company’s stock valued at $55,756,000 after acquiring an additional 9,976 shares during the last quarter. Catalyst Funds Management Pty Ltd acquired a new position in shares of Biogen during the fourth quarter worth $2,006,000. Finally, Insight Wealth Strategies LLC acquired a new position in shares of Biogen during the fourth quarter worth $5,097,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.